Deciphera Pharmaceuticals

General Information
Business:

We are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies. Our targeted, small molecule drug candidates, designed using our proprietary kinase switch control inhibitor platform, inhibit the activation of kinases, an important family of enzymes, that when mutated or over expressed, are known to be directly involved in the growth and spread of many cancers. We have built a diverse pipeline of wholly owned, orally administered drug candidates that includes three clinical-stage and two research-stage programs.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 41
Founded: 2017
Contact Information
Address 500 Totten Pond Road, Waltham, MA 02451, US
Phone Number (781) 209-6400
Web Address http://www.deciphera.com
View Prospectus: Deciphera Pharmaceuticals
Financial Information
Market Cap $542.7mil
Revenues $0 mil (last 12 months)
Net Income $-33.0 mil (last 12 months)
IPO Profile
Symbol DCPH
Exchange NASDAQ
Shares (millions): 7.5
Price range $17.00 - $17.00
Est. $ Volume $127.5 mil
Manager / Joint Managers J.P. Morgan/ Piper Jaffray
CO-Managers JMP Securities/ Nomura
Expected To Trade: 9/28/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change